香港股市 已收市

心通醫療-B (2160.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
0.950-0.010 (-1.04%)
收市:04:08PM HKT

心通醫療-B

No. 1661 Zhangdong Road
Zhangjiang Hi-Tech Park Pudong New District
Shanghai 201203
China
86 21 3895 4600
https://www.cardioflowmedtech.com

版塊Healthcare
行業Medical Devices
全職員工592

高階主管

名稱頭銜支付行使價出生年份
Mr. Jeffrey R LindstromPresident, GM & Executive Director1967
Ms. Luying YanVP & Executive Director1982
Mr. Liang ZhaoExecutive Director & First VP of Total Solutions1980
Ms. Xiangmei LiJoint Company Secretary
Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Secretary1990
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

MicroPort CardioFlow Medtech Corporation, a medical device company, engages in the research, development, and commercialization of transcatheter and surgical solutions for structural heart diseases in the People's Republic of China and internationally. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, Angelguide tip-preshaped super sti¬ff guidewire, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company also provides technical consultation and technical services for medical devices clinical trial. MicroPort CardioFlow Medtech Corporation was founded in 2010 and is headquartered in Shanghai, China.

公司管治

截至 無 止,心通醫療-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。